Assenagon Asset Management S.A. Has $4.10 Million Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Assenagon Asset Management S.A. lowered its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 33.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 573,173 shares of the biotechnology company's stock after selling 283,399 shares during the period. Assenagon Asset Management S.A. owned about 1.14% of REGENXBIO worth $4,098,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of RGNX. JPMorgan Chase & Co. lifted its holdings in REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after acquiring an additional 1,659,206 shares during the last quarter. Millennium Management LLC lifted its stake in REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock valued at $10,222,000 after buying an additional 1,061,187 shares during the last quarter. Balyasny Asset Management L.P. boosted its holdings in shares of REGENXBIO by 6.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company's stock valued at $9,176,000 after acquiring an additional 66,993 shares during the period. Dimensional Fund Advisors LP grew its position in shares of REGENXBIO by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock worth $9,054,000 after acquiring an additional 21,234 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of REGENXBIO by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock worth $8,460,000 after acquiring an additional 5,574 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on RGNX shares. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Monday, June 9th. HC Wainwright cut their price target on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, March 17th. Morgan Stanley increased their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th. Finally, Wall Street Zen raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Price Performance

Shares of RGNX traded down $0.11 during midday trading on Monday, reaching $9.16. The stock had a trading volume of 1,022,196 shares, compared to its average volume of 927,112. The company has a market capitalization of $459.47 million, a P/E ratio of -1.82 and a beta of 1.09. The firm's 50 day moving average price is $8.45 and its 200-day moving average price is $7.92. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $15.36.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The firm had revenue of $89.01 million during the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. On average, equities analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Kenneth T. Mills sold 20,602 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the sale, the director now directly owns 475,103 shares in the company, valued at approximately $3,758,064.73. The trade was a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.79% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.